British regulators said they have identified 30 cases of rare blood clot events after the use of the AstraZeneca Covid-19 vaccine – from a total of 18.1 million doses.
This is 25 more than previously reported.
The Medicines and Healthcare products Regulatory Agency said it had received no such reports of clotting events following use of the vaccine made by Pfizer-BioNTech.
The health officials said they still believe the benefits of the vaccine in the prevention of Covid-19 far outweigh any possible risk of blood clots.
Some have restricted access to the AstraZeneca vaccine over reports of blood clotting, but the EU’s drug regulating agency said earlier this week it had found no specific risk factors connecting the jab to the clots.
However, the European Medicines Agency added: “A causal link with the vaccine is not proven, but is possible and further analysis is continuing.”
On 18 March, the UK medicines regulator said that there had been five cases of a rare brain blood clot among 11 million administered shots.
But the MHRA has now revised this and put the count at 22 reports of cerebralvenous sinus thrombosis, an extremely rare brain clotting ailment.
It also cited eight reports of other clotting events associated with low blood platelets out of a total of 18.1 million doses given.